News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Daiichi Sankyo Co Ltd. Buys 20 Percent Stake in Ranbaxy Laboratories
October 17, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Oct 17 (Reuters) - Japan's Daiichi Sankyo Co said on Friday it had completed the purchase of 20 percent in India's Ranbaxy Laboratories, part of its plan to obtain a majority holding in the generic drugmaker.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Asia
MORE ON THIS TOPIC
Earnings
Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama
November 5, 2025
·
5 min read
·
Annalee Armstrong
Podcast
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
November 5, 2025
·
1 min read
·
Heather McKenzie
Earnings
Pfizer Fields Novo’s $10B Curveball, With Bourla Promising To Fight for Metsera
November 4, 2025
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions
Novo Ups Ante In Metsera Buyout Drama With $10B Offer, Beating Pfizer’s New Bid
November 4, 2025
·
1 min read
·
Annalee Armstrong
